BioTech Breakthrough Singles Out Courier Health For 2026 “Overall BioPharma Solution of the Year”

Courier Health was named “Overall BioPharma Solution of the Year” in the sixth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Courier Health offers a software solution for Patient Services and Field Access & Reimbursement teams. The solution handles patient-centric data entities, compliance complexities, and multi-stakeholder coordination for omnichannel patient experiences. Each brand and team benefit from different data integrations, like hub, SP, data aggregator, as well as journey milestones, and dynamic workflows.

In addition, Courier Health is AI-native, built around specific workflows, roles, and decisions driving patient access and support. A data- and context-rich foundation powers two forms of AI working together to improve patient outcomes. Embedded efficiency tools such as profile summaries, automated reporting, and next-best actions help teams streamline work, while agents designed and trained specifically for biopharma work autonomously to handle high-volume tasks like intake processing, denial appeals, and information requests, while humans stay in the loop as the final check.  

“Companies using Courier Health are achieving measurable improvements across the patient journey, including increases in patient starts and 6-month persistency rates, as well as significant improvement in time-to-therapy. Just last year, we quadrupled the number of customers and therapies using our platform,” said Danny Sigurdson, Founder and CEO of Courier Health.

“We’re pleased to accept ‘Overall BioPharma Solution of the Year’ from BioTech Breakthrough. This incredible recognition underscores our mission to redefine the patient experience for hundreds of millions of people living with a rare disease or chronic condition.”

The life sciences and biotechnology sector is rapidly redefining how diseases are discovered, diagnosed and treated, transforming one of the world's most critical industries. From genomics and gene editing to AI-powered drug discovery, cell and gene therapies, and advanced bioprocessing, biotechnology is delivering faster breakthroughs, more personalized care and better outcomes for patients around the world.

The mission of the annual BioTech Breakthrough Awards program is to recognize the innovators transforming the global biotechnology and life sciences landscape with breakthrough technology. The program conducts a comprehensive analysis of the companies redefining how therapies are researched, developed, manufactured and delivered. From AI-driven drug discovery platforms and precision medicine to synthetic biology, bioinformatics, and next-generation diagnostics and biomanufacturing, these innovations are enabling life sciences organizations to accelerate research, reduce development costs, bring life-changing treatments to market faster, and shape the future of human health.

“Courier Health is solving one of biopharma's most persistent challenges. Fragmented data and manual workflows prevent teams from efficiently engaging patients and providers across the complex care journey. The result is nearly 30% of prescribed patients never beginning treatment, while a startling 70% discontinue within a year,” said Bryan Vaughn, Managing Director, BioTech Breakthrough.

“Courier Health moves beyond legacy life sciences CRM tools by giving biopharma commercial teams a single source of truth - real-time visibility, greater control, and intelligent orchestration over the patient journey. Field Access, Patient Services, and specialty pharma commercial teams now have a command center to power the patient experience.”  

Courier Health supports dozens of specialty therapies spanning a broad range of therapeutic areas, routes of administration, and clinical settings, from oral and injectable treatments to in-office infusions, cell and gene therapies, and across disease states from large-market specialty to ultra-rare.